Literature DB >> 9766615

Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.

.   

Abstract

Adverse effects of antipsychotics often lead to noncompliance. Thus, clinicians should address patients' concerns about adverse effects and attempt to choose medications that will improve their patients' quality of life as well as overall health. The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics. Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain. The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only). Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766615

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

Review 1.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

3.  Managing anticholinergic side effects.

Authors:  Joseph A Lieberman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 4.  Zotepine for schizophrenia.

Authors:  P DeSilva; M Fenton; J Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 5.  Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.

Authors:  William A Hargreaves; P Joseph Gibson; Joseph P Gibson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  Cardiovascular adverse effects of antipsychotic drugs.

Authors:  N A Buckley; P Sanders
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

Review 7.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Loxapine for schizophrenia.

Authors:  A Chakrabarti; A Bagnall; P Chue; M Fenton; V Palaniswamy; W Wong; J Xia
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  The use of atypical antipsychotics in French psychiatric hospitals.

Authors:  Marie Christine Bret; Pierre Bret; Antoine Pariente; Annie Fourier-Réglat
Journal:  Pharm World Sci       Date:  2007-07-19

10.  The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Authors:  Esther Garcia; Marta Robert; Francesc Peris; Hiroshi Nakamura; Noriko Sato; Yoshikatsu Terazawa
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.